How Neoliberal Venture Capital and Genetic Data Colonialism Reshaped 23andMe’s Cyclical Crisis
Original framing: “The Rise, Bankruptcy and Rebirth of 23andMe” — Bloomberg
The voices of patients harmed by 23andMe’s misdiagnoses, low-income communities exploited as test subjects, or racial minorities excluded from genetic databases are entirely absent. For example, Black women have reported being denied health insurance due to 23andMe’s flawed breast cancer risk assessments, yet these stories are framed as ‘isolated incidents’ rather than systemic failures. Marginalized voices also include genetic counselors who warn about the psychological harms of consumer genetic testing, or bioethicists advocating for data reciprocity—none of which are represented in the mainstream narrative.
23andMe’s cyclical crisis is not an isolated corporate failure but a symptom of biocapitalism’s deeper contradictions: the tension between treating genetic data as both a sacred communal resource and a tradable commodity.
The original narrative obscures how Silicon Valley’s venture capital logic—driven by short-term profits and racialized data biases—collides with Indigenous genetic sovereignty movements and global South bioethical frameworks. Historical precedents, from eugenics to pharmaceutical patenting of Indigenous DNA, reveal that each ‘rebirth’ of such companies repeats the same extractive patterns unless structural reforms—like data sovereignty laws, community-led cooperatives, and algorithmic transparency—are enforced. The trickster dimension exposes the absurdity of framing genetic exploitation as ‘innovation,’ while the artistic and spiritual lenses remind us that DNA is not just data but a living narrative deserving of ethical stewardship. Without addressing these systemic imbalances, 23andMe’s ‘rebirth’ will merely be another chapter in the colonial extraction of genetic knowledge.